Display options
Cite
Minuti G, Landi L. MET deregulation in breast cancer. Ann Transl Med. 2015;3(13):181doi: 10.3978/j.issn.2305-5839.2015.06.22.
Minuti, G., & Landi, L. (2015). MET deregulation in breast cancer. Annals of translational medicine, 3(13), 181. https://doi.org/10.3978/j.issn.2305-5839.2015.06.22
Minuti, Gabriele, and Landi, Lorenza. "MET deregulation in breast cancer." Annals of translational medicine vol. 3,13 (2015): 181. doi: https://doi.org/10.3978/j.issn.2305-5839.2015.06.22
Minuti G, Landi L. MET deregulation in breast cancer. Ann Transl Med. 2015 Aug;3(13):181. doi: 10.3978/j.issn.2305-5839.2015.06.22. PMID: 26366398; PMCID: PMC4543340.
Copy Download .nbib Format: NLM
Share it on

Ann Transl Med. 2015 Aug;3(13):181. doi: 10.3978/j.issn.2305-5839.2015.06.22.

MET deregulation in breast cancer.

Annals of translational medicine

Gabriele Minuti, Lorenza Landi

Affiliations

  1. Department of Medical Oncology, Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy.

PMID: 26366398 PMCID: PMC4543340 DOI: 10.3978/j.issn.2305-5839.2015.06.22

Abstract

BACKGROUND: Mesenchymal-epithelial transition (MET) is an oncogene encoding for a trans-membrane tyrosine kinase receptor activated by the hepatocyte growth factor (HGF). MET has a normal function in organ development during embryogenesis and in tissue homeostasis during adult life. Deregulation of HGF/MET signaling pathway is frequently observed in many cancer types, conferring invasive growth and tendency to progression. MET deregulation is due to gene amplification or increased copy number, gene mutation, receptor over-expression or ligand autocrine loops activation. These events lead to migration, invasion, proliferation, metastatic spread and neo-angiogenesis of cancer cells, suggesting that anti-HGF/MET agents may represent a potential antitumor strategy. In breast cancer (BC), preclinical and clinical data demonstrated the role of HGF/MET signalling pathway in carcinogenesis, disease progression and resistance features.

METHODS: For this review article, all published data on HGF/MET in BC were collected and analyzed.

RESULTS: Several evidences underline that, in early BC, MET over-expression has an independent negative prognostic significance, regardless of method used for evaluation and BC subtypes. Available data suggest that MET is a relevant target particularly in basal-like (BL) and in triple negative BC. Moreover, preclinical and retrospective data support the critical role of MET deregulation in the development of resistance to target-agents, such as anti-HER2 strategies.

CONCLUSIONS: MET is a promising new target in BC. Several anti-MET agents are under investigation and ongoing clinical trials will clarify its relevance in BC treatment.

Keywords: Mesenchymal-epithelial transition (MET); basal-like (BL); breast cancer (BC); hepatocyte growth factor (HGF); triple negative

References

  1. Cancer. 2014 Jan 15;120(2):163-71 - PubMed
  2. Cancer Res. 2003 Mar 1;63(5):1101-5 - PubMed
  3. Br J Cancer. 2013 Mar 19;108(5):1100-5 - PubMed
  4. Nature. 1995 Feb 23;373(6516):702-5 - PubMed
  5. Clin Cancer Res. 2014 Jul 1;20(13):3361-3 - PubMed
  6. Int J Cancer. 2014 May 15;134(10):2424-36 - PubMed
  7. Oncogene. 2006 Apr 6;25(15):2273-84 - PubMed
  8. Oncotarget. 2014 Sep 30;5(18):8147-60 - PubMed
  9. Clin Cancer Res. 2012 Apr 15;18(8):2269-77 - PubMed
  10. Cancer Res. 1994 Apr 1;54(7):1630-3 - PubMed
  11. Clin Cancer Res. 2008 Apr 1;14(7):1938-46 - PubMed
  12. Diagn Pathol. 2015 Jun 06;10:62 - PubMed
  13. Tumour Biol. 2006;27(3):115-21 - PubMed
  14. Hum Pathol. 2007 Jun;38(6):830-41 - PubMed
  15. Mol Cell Proteomics. 2008 Aug;7(8):1420-33 - PubMed
  16. Lung Cancer. 1998 Apr;20(1):1-16 - PubMed
  17. Pharmacol Ther. 2014 Sep;143(3):337-49 - PubMed
  18. Histopathology. 2007 Jul;51(1):54-62 - PubMed
  19. Mod Pathol. 2011 Feb;24(2):157-67 - PubMed
  20. Br J Cancer. 2012 Aug 21;107(5):793-9 - PubMed
  21. Breast Cancer Res. 2010;12(4):208 - PubMed
  22. Adv Exp Med Biol. 2008;617:511-7 - PubMed
  23. Int J Cancer. 1999 Sep 9;82(6):908-10 - PubMed
  24. Oncogene. 2006 Jan 19;25(3):409-18 - PubMed
  25. Mol Cancer Res. 2013 Sep;11(9):1112-21 - PubMed
  26. Anticancer Res. 2013 Nov;33(11):5179-86 - PubMed
  27. Science. 1991 Feb 15;251(4995):802-4 - PubMed
  28. Nat Rev Cancer. 2006 Aug;6(8):637-45 - PubMed
  29. J Clin Oncol. 2015 Jan 20;33(3):244-50 - PubMed
  30. J Cell Biol. 1992 Nov;119(3):629-41 - PubMed
  31. J Clin Oncol. 2009 Apr 1;27(10):1667-74 - PubMed
  32. Science. 2007 May 18;316(5827):1039-43 - PubMed
  33. Cancer Discov. 2013 Jun;3(6):658-73 - PubMed
  34. Lab Invest. 1998 Sep;78(9):1143-53 - PubMed
  35. Breast Cancer Res. 2009;11(2):402 - PubMed
  36. Cancer Res. 2008 Mar 1;68(5):1471-7 - PubMed
  37. N Engl J Med. 2001 Mar 15;344(11):783-92 - PubMed
  38. J Clin Oncol. 2011 Dec 20;29(36):4789-95 - PubMed
  39. Cancer. 1999 Dec 1;86(11):2259-65 - PubMed
  40. Int J Cancer. 2005 Feb 10;113(4):678-82 - PubMed

Publication Types